Drug intelligence / Profile preview

IPX237

Development stage: Unknown
Lead developer: Amneal Pharmaceuticals
Modality: Small Molecules
Administration: Sublingual

Overview

IPX237 is an investigational sublingual formulation of esketamine, the S-enantiomer of ketamine, developed by Impax Pharmaceuticals (a division of Impax Laboratories, now part of Amneal Pharmaceuticals). It acts as a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. The drug was primarily explored for the treatment of depression, specifically targeting treatment-resistant depression (TRD), by leveraging the rapid-acting antidepressant properties of esketamine. Clinical development included Phase 1 pharmacokinetic and safety studies in healthy volunteers to evaluate the sublingual delivery route, which aims to provide a more convenient administration method compared to intravenous or intranasal options.

Other names: sublingual esketamine

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on IPX237.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPX237.

Explore the full profile